U.S. Pharmacist eNewsletter
March 2022

First Participant Dosed in HIV Trimer mRNA Vaccine

Moderna, Inc. recently announced that the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized, phase I trial is designed to assess the safety and immunogenicity of experimental HIV trimer mRNA vaccines. Learn more about this experimental HIV trimer mRNA vaccine.


Adverse Effects With COVID-19 Vaccines Are Mild, Short-Lived
In a recent publication in The Lancet Infectious Diseases, researchers conducted an observational study and analyzed data reported to the Vaccine Adverse Event Reporting System and v-safe. The researchers indicated that in a review of the data from the first 6 months after initiation of the mRNA COVID-19 vaccines, the reported adverse effects were generally mild and short-lived. Read more.

Waning Effectiveness After Third COVID-19 Vaccine Dose
Findings from a new study reveals that immunity against severe COVID-19 disease starts to wane 4 months after receipt of the third dose of an mRNA vaccine. Waning immunity was detected during both the Delta and Omicron variant waves in comparable fashion to how mRNA vaccine effectiveness wanes after a second dose. Learn more about what the data revealed in this study.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App